Derek Nexus and Sarah Nexus: working together for ICH M7
|
|
|
- Noel Dean
- 9 years ago
- Views:
Transcription
1 Derek Nexus and Sarah Nexus: working together for ICH M7 European ICGM, September 2014 Dr Nicholas Marchetti Product Manager
2 Derek Nexus and Sarah Nexus: working together for ICH M7 OUTLINE Impact of changes driven by M7 In silico solutions Vitic Nexus an authoritative toxicity database Derek Nexus the leading expert system Sarah Nexus an advanced statistical system Expert assessment from 2 predictions
3 What does M7 cover? identification categorisation qualification Control of mutagenic impurities to limit potential carcinogenic risk Harmonises guidelines FDA, EMA, Japan Recognises the primacy of the Ames assay
4 Focussing on the identification step Evaluate drug substance, impurities, degradants, (metabolites), intermediates Databases, in-house, literature.. 2 x in silico QSAR Leadscope Multicase Known mutagen Predicted positive Predicted negative Known non-mutagen Expert Review Ames test Expert Review Limit according to TTC or present purge argument for absence Treat as nonmutagenic
5 Derek Nexus and Sarah Nexus: working together for ICH M7 OUTLINE Impact of changes driven by M7 In silico solutions Vitic Nexus an authoritative toxicity database Derek Nexus the leading expert system Sarah Nexus an advanced statistical system Expert assessment from 2 predictions
6 Vitic Nexus an authoritative toxicity database Vitic Nexus is a repository of toxicological data Data donated by members Curated and augmented by expert scientists Genotoxicity records In vitro data In vivo data Overall call 146,444 records, 9,014 compounds 10,157 records, 2,658 compounds 15,289 records, 8,510 compounds Contains public datasets and literature including Benchmark, CGX, ISSSTY, IUCLID FDA CDER & CFSAN, JETOC (Japanese Chemical Industry Ecology-Toxicology..) IARC, JETOC, NIHS, NTP, SCCP, SIDS Members also store their own data in Vitic Nexus
7 Data sharing consortia Lhasa facilitate pre-competitive data sharing Members of these consortia also see Aromatic amines 1,664 records 145 compounds Intermediates (includes boronic acid sub-group) 13,834 records 910 compounds Excipients 2,286 records 764 compounds
8 in silico predictions for M7 Use models that predict Ames outcomes 2 complementary methods should be applied One expert rule-based One statistical-based Models should follow OECD Principles for QSAR The absence of alerts from both is sufficient to conclude that the impurity is of no concern Expert review is needed to provide additional evidence for any prediction and to explain conflicting results
9 Derek Nexus and Sarah Nexus: working together for ICH M7 OUTLINE Impact of changes driven by M7 In silico solutions Vitic Nexus an authoritative toxicity database Derek Nexus the leading expert system Sarah Nexus an advanced statistical system Expert assessment from 2 predictions
10 Enhancing Derek Nexus for mutagenicity Designed to support expert analysis for M7 Provide additional supporting information Recommend where expert should focus analysis
11 Derek Nexus and Sarah Nexus: working together for ICH M7 OUTLINE Impact of changes driven by M7 In silico solutions Vitic Nexus an authoritative toxicity database Derek Nexus the leading expert system Sarah Nexus an advanced statistical system Expert assessment from 2 predictions
12 Sarah Nexus an advanced statistical system Designed to address the ICH M7 guidelines Created with input from the FDA under a Research Collaboration Agreement
13 Making a prediction Query compounds are fragmented Each fragment is assessed Fragments not covered by the training set result in no prediction Relevant hypotheses for each fragment are retrieved Hypothesis, signal, confidence, supporting examples Typically several hypotheses are returned out of domain Overall Prediction = f (prediction, confidence) hypotheses Absence of a strong overall signal equivocal
14 Confidence correlates with accuracy TN 29% TP 31% FP 22% FN 18% TN 40% FP 13% TP 37% FN 10% TN 39% FP 9% TP 50% FN 2% TN 34% FP 4% TP 60% FN 2% FP 6% TN 23% TP 70% FN 1% 1 b. aaa = ssss + ssss PPP = TT TT + FF 0.6 NNN = TT TT + FF % 20-40% 40-60% 60-80% % Sarah confidence score
15 Confidence vs PPV 100% 90% 80% 70% PPV 60% 50% 40% 30% 20% 10% 0% 0% 20% 40% 60% 80% 100% Confidence
16 Sarah Nexus Performance Sarah Nexus has been extensively evaluated by members 100% 80% 83-96% 60-85% 60-89% 38-84% 60% Private 1, n= 744, 28% +ive Private 2, n = 847, 12% +ive Private 3, n= 437, 16% +ive 40% 20% 0% sens + spec 2 TN TN + FP TP TP + FN Coverage Balanced accuracy Specificity Sensitivity Private 4, n = 986, 4% +ive Private 5, n = 1718, 14% +ive Private 6, n = 320, 23% +ive FDA, n=809, 36% +ive Public, n = 11209,49% +ive Sarah Nexus v1 under recommended settings SoT, March 2014
17 Sarah Nexus - Summary Sarah is a statistical approach to mutagenicity Maintains high coverage even with challenging datasets Provides information needed for expert analysis
18 The use of integrated in silico solutions under the proposed ICH M7 guidelines OUTLINE Impact of changes driven by M7 In silico solutions Vitic Nexus an authoritative toxicity database Derek Nexus the leading expert system Sarah Nexus an advanced statistical system Expert assessment from 2 predictions
19 Using in silico predictions M7 explicitly states that in silico predictions should be reviewed with expert knowledge Provide supportive evidence for any prediction Elucidate underlying reasons in case of conflicting results But how will this work in real life? In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: An industry survey Regulatory Toxicology and Pharmacology, 2012, 62, Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities Regulatory Toxicology and Pharmacology, 2013, 67, 39
20 2 complementary methodologies should be applied Data methodology Expert system uses all Lhasa data including consortia & donated confidential data + data mined on-site expert system human-written rules based upon data & knowledge Statistical system only uses non-confidential data statistical model machine-learning model using a hierarchical network scope of alert hand-written Markush fragments learnt by model interpretability references expert commentary mechanistic explanation scope of alert some supporting examples transparent methodology learning summarised by hypothesis direct link to training set confidence in prediction
21 Using Sarah and Derek together How often do they disagree? When they agree, how accurate are they? 100% 69-85% 62-90% 80% 60% 40% 20% Private Dataset 1 Private Dataset 2 Private Dataset 3 Public Dataset 0% Agreement between Derek Nexus and Sarah Nexus Balanced accuracy for concurring predictions Acknowledgements : All the Lhasa members who worked closely with us during the evaluation and development of Sarah
22 Using Sarah and Derek together A simple conservative approach will increase sensitivity sensitivity 1..but at the cost of accuracy and specificity , = Private dataset accuracy specificity
23 Using Sarah and Derek together When they disagree, which is right? Public Dataset Private Dataset 3 7% 14% 7% 7% 11% 9% 5% 7% 9% 72% 73% 80% 31% 25% 17% 27%
24 Handling conflicting predictions Confidence scores can give an indication Machine-learnt & expert driven rules have been assessed If both models agree Take that consensus prediction If one model has a high confidence prediction Take the most confident prediction If Derek says positive and Sarah has a positive hypothesis (despite being negative overall) Activity is most likely If the positive prediction is of low confidence Activity is unlikely.
25 Handling conflicting predictions Private Dataset 1 Step Step 2 Step 3 Step 4 D and S agree Most confident prediction D says positive, S has positive hypothesis Low confidence positive Accuracy Sensitivity True accuracy Coverage Simple rules give increased coverage without loss of accuracy
26 Ultimately, expert review is needed Decision trees may help guide an expert, but expert review is still essential We have worked with our members to deliver the information needed for expert review
27 Supporting the expert workflow Step 1 Specific Prediction for ICH M7
28 Supporting the expert workflow Derek prediction Predicted negative but there is a ring system to assess
29 Supporting the expert workflow Derek Nexus now shows those compounds from the Lhasa Ames test reference set most closely related to the query
30 Supporting the expert workflow Step 2 Sarah prediction Sarah predicts negative; no positive hypotheses seen Derek and Sarah analysis agree Supporting data from Vitic augments this prediction
31 Supporting the expert workflow Step 3 Vitic search similarity chosen Vitic shows a related active for which there is no obvious cause (no Derek alert fires) and also a related inactive Expert assessment ring system not of concern
32 Possible reasons to over-rule a positive in silico call The presence of a second confounding alert that could have caused the activity a risk with statistical models Minimised with Sarah s recursive learning approach Mechanistic interpretation stereo-electronics preclude reaction through the accepted mechanism such as that described within Derek Similar analogues trigger the same alert and have been tested as inactive were not known to the model
33 What our members say Combined use of two complementary in silico systems such as Derek Nexus and SEP leads to an increase in negative predictivity and sensitivity, up to 99.1% and 94.7% respectively Poster Comparative Evaluation of in Silico Systems for Ames Test Mutagenicity Prediction Ilse Koijen Janssen, GTA Newark Oct 2013, SEP = the pre-release version of Sarah
34 Combined report view
35 Derek Prediction
36 Sarah Prediction
37 Batch View
38 Paper reports
39 Summary M7 will allow predictions of mutagenicity to be submitted Derek has been extended to increase support for expert review Making confident predictions of inactivity Highlighting features worthy of attention Sarah has been designed to provide the statistical 2 nd system Recursive learning and a hierarchical network provide transparency and accuracy The performance of combined predictions has been described Using a number of relevant confidential datasets Examples of expert decision-making illustrate their application Use of Vitic, an authoritative database supports this workflow
40 Questions?
is a knowledge based expert decision support tool for predicting the metabolic fate of chemicals in mammals.
is a knowledge based expert decision support tool for predicting the metabolic fate of chemicals in mammals. Reference 08/15 Features and Benefits Summary Efficient Metabolite Structure Elucidation Early
ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC) IMPURITIES IN PHARMACEUTICALS TO LIMIT POTENTIAL CARCINOGENIC RISK
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC)
Chemical Risk Assessment in Absence of Adequate Toxicological Data
Chemical Risk Assessment in Absence of Adequate Toxicological Data Mark Cronin School of Pharmacy and Chemistry Liverpool John Moores University England [email protected] The Problem Risk Analytical
EDQM: 50 YEARS OF LEADERSHIP IN THE QUALITY OF MEDICINES PAVING THE WAY FOR THE FUTURE
EDQM: 50 YEARS OF LEADERSHIP IN THE QUALITY OF MEDICINES PAVING THE WAY FOR THE FUTURE 6-8 October 2014 Strasbourg, France WORKSHOP IMPURITIES 1 Workshop Session IMPURITIES DNA-reactive impurities: An
Mutagenic Impurity Risk Assessment Purge Tool Supporting ICH M7 Control Strategy
Mutagenic Impurity Risk Assessment Purge Tool Supporting ICH M7 Control Strategy Ella Smoraczewska Lhasa Limited Sales Executive Presentation utline Background & Case Study Regulatory Perspective MI Purge
IMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Q3B(R2) Current
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES
In Silico Models: Risk Assessment With Non-Testing Methods in OSIRIS Opportunities and Limitations
In Silico Models: Risk Assessment With Non-Testing Methods in OSIRIS Opportunities and Limitations Mark Cronin, Mark Hewitt, Katarzyna Przybylak School of Pharmacy and Chemistry Liverpool John Moores University
What s New with Impurities in Pharmaceuticals?
What s New with Impurities in Pharmaceuticals? Southern California Pharmaceutical Discussion Group January 15, 2015 Bernard A. Olsen, Ph.D Olsen Pharmaceutical Consulting, LLC [email protected] ICH Q3
QSAR Application Toolbox Workflow. Laboratory of Mathematical Chemistry, Bourgas University Prof. Assen Zlatarov Bulgaria
QSAR Application Toolbox Workflow Laboratory of Mathematical Chemistry, Bourgas University Prof. Assen Zlatarov Bulgaria Outlook Description General scheme and workflow Basic functionalities Forming categories
Importing pharmaceutical products to China
Importing pharmaceutical products to China Imported pharmaceutical products need pre-market approval before entering the Chinese market Imported drugs for human use are required to obtain pre-market approval
Rapid Pharma Development GmbH. Impurities in the contexts of CMC Development
Rapid Pharma Development GmbH Impurities in the contexts of CMC Development The Challenge What is your Goal? What is your path? Plan for Success Define your goal: Target Product Profile Daily dosage Cost
Guidance for Industry
Guidance for Industry Q2B Validation of Analytical Procedures: Methodology November 1996 ICH Guidance for Industry Q2B Validation of Analytical Procedures: Methodology Additional copies are available from:
Regulatory Expectations for GMP: What s Happening. Patricia Weideman, PhD Director, Product Quality & Occupational Toxicology Genentech, Inc.
Regulatory Expectations for GMP: What s Happening Patricia Weideman, PhD Director, Product Quality & Occupational Toxicology Genentech, Inc. Topics Background for changes and expectations of regulatory
Read-across and alternative testing strategies for REACH 2018
Read-across and alternative testing strategies for REACH 2018 Jeannette Paulussen, Ph.D. June 24, 2015 Content REACH & Alternative testing strategies In vitro testing and study waivers QSARs and Annex
How to create and interpret the predictive analysis of a compound
How to create and interpret the predictive analysis of a compound Platform with suite of tools Predict & understand biological effects of small molecules & compounds Predict targets and metabolites, potential
ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5
European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS
Edward Odenkirchen, Ph.D. Office of Pesticide Programs US Environmental Protection Agency
Edward Odenkirchen, Ph.D. Office of Pesticide Programs US Environmental Protection Agency 1 Mission Statement Best possible regulatory decisions to protect public health and environment. Rely on all best
Practical Guide 6. How to report read-across and categories
Practical Guide 6 How to report read-across and categories 2 Practical Guide 6 2.0 Version Changes Date Version 1.0 First version. March 2010 Version 2.0 Revision of the Practical guide addressing structure
General Principles for the Safety Assessment of Excipients
General Principles for the Safety Assessment of Excipients General Characteristics of the Pharmaceutical Excipients Classification of excipients The Safety Assessment of Pharmaceutical Excipients : how
Guidance for Industry Safety Testing of Drug Metabolites
Guidance for Industry Safety Testing of Drug Metabolites U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2008 Pharmacology
Risk assessment and regulation of tattoo inks in the EU
Risk assessment and regulation of tattoo inks in the EU Paul Janssen Current situation: Tattoo application in a regulatory vacuum : Is not a medical treatment Is not a cosmetic treatment No EU-regulation
A FDA Perspective on Nanomedicine Current Initiatives in the US
A FDA Perspective on Nanomedicine Current Initiatives in the US Carlos Peña, PhD Office of the Commissioner FDA September 3, 2010 Outline Context Nanotechnology Task Force report summary Identification
Risk Management in the Pharmaceutical Industry. Elena Apetri, Global Medical Safety Surveillance Schering AG
Risk Management in the Pharmaceutical Industry Elena Apetri, Global Medical Safety Surveillance Schering AG Topics Environment Safety Risk Management Guidance Safety RM Systems Signal detection and evaluation
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution
From QSAR to Big Data: Developing Mechanism-Driven Predictive Models for Animal Toxicity
From QSAR to Big Data: Developing Mechanism-Driven Predictive Models for Animal Toxicity Hao Zhu Department of Chemistry The Rutgers Center for Computational and Integrative Biology Rutgers University-Camden
Working with ICH Quality Guidelines - the Canadian Perspective
Working with ICH Quality Guidelines the Canadian Perspective Krishnan Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences Therapeutic Products Directorate Health Canada December 3, 2008 Outline Introduction
NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1)
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY
Overview of Drug Development: the Regulatory Process
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
TYPICAL FDA COMMENTS ON IMPURITY PROFILING IN CTD/CEP/DMF SUBMISSIONS
TYPICAL FDA COMMENTS ON IMPURITY PROFILING IN CTD/CEP/DMF SUBMISSIONS By Rajkumar Gupta, Managing Director Perfect Pharmaceutical Consultant Pvt. Ltd and Director Global Institute of Regulatory affairs,
Guidance for Industry
Guidance for Industry S9 Nonclinical Evaluation for Anticancer Pharmaceuticals U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
Division of Bioinformatics and Biostatistics
Division of Bioinformatics and Biostatistics Weida Tong, Ph.D. The views presented do not necessarily reflect the views of the FDA. 1 Established on May 20 th, 2012. Three Branches: Division Overview Bioinformatics
REACH. Scope REGISTRATION. The Current EU Chemicals Policy REACH
Introduction to the New Chemicals Policy REACH REACH and Developing Countries Brussels 28-29 October 2004 Eva Sandberg DG Environment, European Commission The Current EU Chemicals Policy Problems Existing
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance
CTD Dossier Preparation. Sr.Manager-Regulatory Affairs
CTD Dossier Preparation K. Srikantha Reddy Sr.Manager-Regulatory Affairs Medreich Limited [email protected] CTD Dossier Preparation CTD (Common Technical Document) contains 5 modules Module 1 Module
Examples from Industrial Practice in Lead Development. Wolfgang Muster F. Hoffmann-La Roche Ltd.
Examples from Industrial Practice in Lead Development Wolfgang Muster F. Hoffmann-La Roche Ltd. Areas Computer-Aided Molecular Modeling (CAMM) * Absorption, Distribution, Metabolism and Excretion (ADME)
MedDRA in pharmacovigilance industry perspective
MedDRA in pharmacovigilance industry SFDA ICH MedDRA Workshop, Beijing, 13 14 May 2011 Christina Winter, MD, FFPM Medical director GlaxoSmithKline R&D / ICH MedDRA Management Board 2011 ICH International
Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants
Cleaning Validation in Active pharmaceutical Ingredient manufacturing plants September 1999 Table of contents 1. Foreword...... 2 2. Objective...... 3 3. Scope........ 4 4. Potential residues... 5 5. Current
Submission of scientific peer-reviewed open literature for the approval of pesticide active substances under Regulation (EC) No 1107/2009 1, 2
GUIDANCE OF EFSA - DRAFT Submission of scientific peer-reviewed open literature for the approval of pesticide active substances under Regulation (EC) No 1107/2009 1, 2 ABSTRACT European Food Safety Authority
Biological importance of metabolites. Safety and efficacy aspects
Biological importance of metabolites Safety and efficacy aspects Bernard Walther Technologie Servier Biological importance of metabolites Safety testing of drug metabolites Bioanalytical strategy Structural
Medicine Safety Glossary
The following definitions are provided as a resource to supplement the information provided in the Medicine Safety Education section of the Pfizer.com Web site; they are not intended as a comprehensive
Guidance for Industry
Guidance for Industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products Center for
Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry
Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high
Impurity Profiles in Active Pharmaceutical Ingredients
Impurity Profiles in Active Pharmaceutical Ingredients EU/Swissmedic GMP Workshop Beijing University, Sept. 20 22, 2006 Dr. Susanne Keitel Federal Institute for Drugs and Medical Devices (BfArM), Germany
Validating Methods using Waters Empower TM 2 Method. Validation. Manager
Validating Methods using Waters Empower TM 2 Method Validation Manager (MVM) Anders Janesten Nordic Informatics Sales Specialist 2008 Waters Corporation Decision-centric centric method development information
Drug Information Journal, Vol. 33, pp. 755 761, 1999 0092-8615/99
Drug Information Journal, Vol. 33, pp. 755 761, 1999 0092-8615/99 Printed in the USA. All rights reserved. Copyright 1999 Drug Information Association Inc. THE ACTIVE PHARMACEUTICAL INGREDIENTS STARTING
Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials
Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials Ron Hinkel, Director Quality Systems BioReliance Inc. Patti Rossman, President Globiox Purpose Keep pace
BBSRC TECHNOLOGY STRATEGY: TECHNOLOGIES NEEDED BY RESEARCH KNOWLEDGE PROVIDERS
BBSRC TECHNOLOGY STRATEGY: TECHNOLOGIES NEEDED BY RESEARCH KNOWLEDGE PROVIDERS 1. The Technology Strategy sets out six areas where technological developments are required to push the frontiers of knowledge
Implementation strategy for ISO IDMP in EU
Implementation strategy for ISO IDMP in EU Paolo Alcini Head of Data Standardisation and Analytics Business Data & Analytics Information Management EMA An agency of the European Union The EU ISO IDMP Task
ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities)
November 2012 EMA/CHMP/ICH/425213/2011 ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities) Step 5 Transmission to CHMP May
ICH Public Meeting. Joseph C. Famulare. October 2, 2006. Acting Deputy Director Office of Compliance CDER / FDA Office of Compliance
ICH Public Meeting October 2, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA Office of Compliance The Current State of Pharmaceutical Manufacturing Inability to predict
Strategic Benefits of an Online Clinical Data Repository
Strategic Benefits of an Online Clinical Data Repository 5625 Dillard Drive Suite 205 Cary, NC 27518 www.pharsight.com Strategic Benefits of an Online Clinical Data Repository Contents Introduction 2 The
ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. Step 5
European Medicines Agency June 1995 CPMP/ICH/381/95 ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology Step 5 NOTE FOR GUIDANCE ON VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND
GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS.
GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS October 2004 APVMA PO Box E240 KINGSTON 2604 AUSTRALIA http://www.apvma.gov.au
The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers.
Supplier Quality Standard 1.0 Purpose The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers. These expectations
Getting Ready for REACH Advanced Solutions for Compliance. John Phyper, CSO & EVP Atrion International Inc.
Getting Ready for REACH Advanced Solutions for Compliance John Phyper, CSO & EVP Atrion International Inc. Getting Ready for REACH Advanced Solutions for Compliance Introduction What is REACH? What Does
Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle
Quality Risk Management 11 November 2011 Galway, Ireland Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Overview Regulatory
C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to
C 5 chemical development contract research custom synthesis cgmp API manufacturing commercial production Welcome to ChemCon Company profile Company profile ChemCon offers outstanding chemical services
Guidance for Industry
Guidance for Industry Scientific Considerations in Demonstrating Biosimilarity to a Reference Product DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and
NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES Division of Extramural Research and Training
NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES Division of Extramural Research and Training NATIONAL ADVISORY ENVIRONMENTAL HEALTH SCIENCES COUNCIL May 12-13, 2010 Concept Clearance Small Business
Q8(R2): Pharmaceutical Development
ICH-GCG ASEAN Q8(R2): Pharmaceutical Development Jean-Louis ROBERT, Ph.D. National Health Laboratory, Luxembourg Chair-person ICH IWG Q8, Q9, Q10 Kuala Lumpur, 26-28 July 2010 International Conference
International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation
International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation Ludwig Huber, Ph.D. [email protected] Overview GMP requirements for Quality Control laboratories
Alterações empresariais sustentadas pelo conceito de engenharia do Produto Patrício Soares da Silva, MD, PhD
Alterações empresariais sustentadas pelo conceito de engenharia do Produto Patrício Soares da Silva, MD, PhD 1 Summary Hypothesis Generation Candidate Development Commercialization Target Identification
Chapter 12: SPECIFIC TARGET ORGAN SYSTEMIC TOXICITY (TOST) FOLLOWING A SINGLE EXPOSURE
Chapter 12: SPECIFIC TARGET ORGAN SYSTEMIC TOXICITY (TOST) FOLLOWING A SINGLE EXPOSURE DEFINITIONS 1. Classification identifies the chemical substance as being a specific target organ/systemic toxicant
Risk Assessment in Chemical Food Safety. Dept. of Food Safety and Zoonoses (FOS) http://www.who.int/foodsafety/en/
Risk Assessment in Chemical Food Safety Dept. of Food Safety and Zoonoses (FOS) http://www.who.int/foodsafety/en/ Risk Analysis Paradigm Internationally Scientific data analysis Risk Assessment WHO & FAO
Lead optimization services
Lead optimization services The WIL Research Company (WRC) has extensive experience in fast track tailor-made screening strategies to help you with the challenging task of selecting your best candidate
ANTARES A new project for Alternative Methods and REACH
newsletter October 2010 ANTARES A new project for Alternative Methods and REACH Alternative Non-Testing methods Assessed for REACH Substances www.antares-life.eu LIFE08 ENV/IT/00435 2 ANTARES Newsletter
Use of Predictive ADME in Library Profiling and Lead Optimization
Use of Predictive ADME in Library Profiling and Lead Optimization Osman F. Güner and Robert D. Brown 223 rd ACS National Meeting April 2002, Orlando Florida Why Predictive ADME in Early Discovery? The
Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences
Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences It s not information overload, it s filter failure. Clay Shirky Life Sciences organizations face the challenge
Causality Assessment in Practice Pharmaceutical Industry Perspective. Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd.
Causality Assessment in Practice Pharmaceutical Industry Perspective Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd., Basel Disclaimer: The opinions expressed in this presentation are
Ah-Reum Seo of Chemservice Asia introduces the forthcoming chemicals regulation for South Korea
Environment & Regulations The best strategy to implement K-REACH Ah-Reum Seo of Chemservice Asia introduces the forthcoming chemicals regulation for South Korea Most existing chemicals on the market have
Overview of Key Obligations Under Regulation (EC) No. 1272/2008 on the Classification, Labelling and Packaging of Substances and Mixtures (CLP)
Overview of Key Obligations Under Regulation (EC) No. 1272/2008 on the Classification, Labelling and Packaging of Substances and Mixtures (CLP) Summary This document examines the key aspects of the CLP
ROADMAP. A. Context and problem definition
ROADMAP TITLE OF THE INITIATIVE Defining criteria for identifying Endocrine Disruptors in the context of the implementation of the Plant Protection Product Regulation and Biocidal Products Regulation LEAD
Current version dated 5 March 2012
M3(R2) Implementation Working Group M3(R2) Guideline: Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Questions & Answers
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E15
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE DEFINITIONS FOR GENOMIC BIOMARKERS, PHARMACOGENOMICS,
ICH M3 (R2) Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
ICH M3 (R2) Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals International Conference on Harmonisation of Technical Requirements
Chemical Screening Visualization Tool: Resource for Rapid Chemical Assessment
Chemical Screening Visualization Tool: Resource for Rapid Chemical Assessment Mario Chen Environmental & Toxicological Modeling DuPont Haskell Global Centers for Health & Environmental Sciences 2 Abstract
Non-clinical development of biologics
Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service
Guidance for Industry COMPUTERIZED SYSTEMS USED IN CLINICAL TRIALS
Guidance for Industry COMPUTERIZED SYSTEMS USED IN CLINICAL TRIALS U.S. Department of Health and Human Services Food and Drug Administration Center for Biologic Evaluation and Research (CBER) Center for
Goals & Objectives. Drug Development & the FDA Pharmacy 309. Outline. An History of Disasters. Be able to describe
Drug Development & the FDA Pharmacy 309 Tom Hazlet, Pharm.D., Dr.P.H. 616-2732 thazlet@u... Goals & Objectives Be able to describe the major regulatory events in the drug development process the concepts
Workshop B Control Strategy
ICH-GCG ASEAN Workshop B Control Strategy Jean-Louis ROBERT, Ph.D. National Health Laboratory, Luxembourg Chair-person ICH IWG Q8, Q9, Q10 Kuala Lumpur, 26-28 July 2010 International Conference on Harmonisation
Collaborations between Official Statistics and Academia in the Era of Big Data
Collaborations between Official Statistics and Academia in the Era of Big Data World Statistics Day October 20-21, 2015 Budapest Vijay Nair University of Michigan Past-President of ISI [email protected] What
Roles & Responsibilities of the Sponsor
Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from
Cheminformatics and its Role in the Modern Drug Discovery Process
Cheminformatics and its Role in the Modern Drug Discovery Process Novartis Institutes for BioMedical Research Basel, Switzerland With thanks to my colleagues: J. Mühlbacher, B. Rohde, A. Schuffenhauer
Dr Alexander Henzing
Horizon 2020 Health, Demographic Change & Wellbeing EU funding, research and collaboration opportunities for 2016/17 Innovate UK funding opportunities in omics, bridging health and life sciences Dr Alexander
Auditing as a Component of a Pharmaceutical Quality System
Auditing as a Component of a Pharmaceutical Quality System Tim Fields Conducting internal audits (or self inspections) and external audits of suppliers and outsourcing operations are key elements of a
GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.
15 January 2007 GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.) TABLE OF CONTENTS 1 INTRODUCTION... 2 2
An FDA Perspective on Post- Approval Change Management for PAT and RTRT
An FDA Perspective on Post- Approval Change Management for PAT and RTRT IFPAC 2015 January 26, 2015 Christine M. V. Moore, Ph.D. Acting Director, Process and Facilities FDA/CDER/OPQ Post-Approval Changes
Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements
Bachelor of Science in Pharmaceutical Sciences (BSPS) Program Overview and Internship Requirements Pharmaceutical Sciences Applied sciences that underlie the practice of pharmacy the development, manufacture,
SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS S7A
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS
